Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients
Authors:
- Paul A. GurbelPGPaul A. Gurbel
- Kevin P. BlidenKBKevin P. Bliden
- Amena EtheringtonAEAmena Etherington
- Udaya S. TantryUTUdaya S. Tantry
- 1 January 2007
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 121 (1) , 107-115
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective StentingJACC, 2006
- Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialAmerican Heart Journal, 2006
- Clopidogrel Effect on Platelet REactivity in Patients With Stent ThrombosisJACC, 2005
- Matching the Evaluation of the Clinical Efficacy of Clopidogrel to Platelet Function Tests Relevant to the Biological Properties of the DrugJACC, 2005
- Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of PlateletsCirculation, 2005
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Diversity of signaling underlying responses mediated by selective activation of the platelet thromboxane A 2 (TXA 2 ) receptor; pharmacological and kinetic studies in vitroPlatelets, 2003
- Clopidogrel for Coronary StentingCirculation, 2003
- Deaggregation is an integral component of the response of platelets to ADP in vitro : kinetic studies of literature and original dataPlatelets, 2001
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996